Prognostic Factors For Outcome in Patients with Refractory and Relapsed Acute Lymphocytic Leukemia Treated with Inotuzumab Ozogamicin, a CD22 Monoclonal Antibody

BACKGROUND: Inotuzumab ozogamicin was found to be highly active in patients with refractory-relapsed acute lymphocytic leukemia (ALL), with an overall response rate of 58% and a median survival of 6.3 months. Identifying factors associated with different outcomes on inotuzumab therapy may help selec...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Am J Hematol
Prif Awduron: Jabbour, Elias, O’Brien, Susan, Huang, Xuelin, Thomas, Deborah, Rytting, Michael, Sasaki, Koji, Cortes, Jorge, Garcia-Manero, Guillermo, Kadia, Tapan, Ravandi, Farhad, Pierce, Sherry, Kantarjian, Hagop
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2015
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5505232/
https://ncbi.nlm.nih.gov/pubmed/25407953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23901
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg